FDA taps biotech industry veteran as RFK Jr.’s top drug regulator 

• The Food and Drug Administration said it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator.
• Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University’s School of Medicine, will lead one of the most crucial FDA divisions that reviews the vast majority of new drug applications.
• He brings a long history of drug development experience to the Center for Drug Evaluation and Research, or CDER, which regulates over-the-counter and prescription treatments, including biologic therapies and generics.

The Food and Drug Administration said Monday it has

appointed

former biotech executive George Tidmarsh as the agency’s

top drug regulator

.

Stream San Diego News for free, 24/7, wherever you are with NBC 7.

Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University’s School of Medicine, will lead one of the biggest and most crucial divisions of the FDA, which reviews the vast majority of new drug applications.

The Center for Drug Evaluation and Research, or CDER, regulates over-the-counter and prescription treatments, including biologic therapies and generics. The acting head of CDER, Jacqueline Corrigan-Curay,

announced

in June she was retiring.

Get top local San Diego stories delivered to you every morning with our News Headlines newsletter.

Tidmarsh will step in as the FDA and its regulatory process face massive upheaval under Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy has pursued deep staff cuts across HHS and, in some cases, brought in new employees who either lack relevant scientific and medical experience or share his skepticism of vaccines.

But Tidmarsh’s extensive background in the industry and involvement in the development of seven now-approved drugs is likely a sigh of relief for the pharmaceutical industry. His previous comments signal that he could take a more hard-line approach to regulating drugs.

In an

opinion piece

in April, Tidmarsh slammed regulatory decisions made by a key official pushed out of the FDA under Kennedy, Peter Marks. That includes supporting the

accelerated approval

of

Biogen’

s ill-fated Alzheimer’s drug, Aduhelm, and overruling FDA staff to expand

approval

of

Sarepta Therapeutics

‘ Duchenne muscular dystrophy treatment Elevidys.

Money Report

From California to Gulf Coast, Trump’s trade war take biggest toll on nation’s smaller, secondary ports

39-year-old dermatologist bought a $2 million home outside of Miami—why she’s never lived there

Last week, the FDA asked Sarepta Therapeutics to

halt all shipments

of Ele­vidys after three patients died from liver failure after taking it or a similar treatment. The company later said it would not stop shipments to treat patients with the condition who can still walk, saying data shows “no new or changed safety signals” within that group.

• From ‘Cockroach Award’ to the Big Board: Hinge Health’s unlikely path to IPO

• How UnitedHealthcare became the face of America’s health insurance frustrations

• When 20,000 devices were paralyzed by a bad update, a Georgia health system turned to Apple

In an interview with CNBC on Friday, before the Tidmarsh appointment was announced, Marks said his previous decisions on the gene therapy were “made on the best available knowledge at the time.” At that time, the debate centered around efficacy, not safety, he said.

Marks said he doesn’t think it’s “unreasonable” to ask Sarepta to pause shipments until “you do a real review of everything that is going on.”

Tidmarsh will likely have a say on that controversial accelerated approval process and the FDA’s approach to prescription drug advertising. He served as CEO of La Jolla Pharmaceuticals and Horizon Pharma, the latter of which he founded before

Amgen

bought it for $28 billion. Tidmarsh also founded Threshold Pharmaceutical, and held senior positions at other biotech companies.

“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development—from bench to bedside,” said FDA Commissioner Dr. Marty Makary, in a statement. “His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency.”

— CNBC’s Angelica Peebles contributed to this report.

• Analysts raise Nvidia price targets after Trump’s China chip decision. One sees $5 trillion market cap ahead

• Dividend payouts could hit a record this year. These stocks are Wall Street’s favorites

• Breakup rumors at Kraft Heinz prompt speculation Berkshire Hathaway may be selling its stake

• Coming to a 401(k) near you: Private market assets

Also on CNBC

• Weight loss drugs could be a gamechanger for women with PCOS

• Sarepta plunges as FDA mulls whether gene therapy should stay on market

• Trump diagnosed with common vein condition that causes ankle swelling